What Are SMOF Lipids and How Do They Work?

SMOF lipids are an intravenous fat emulsion made from four different oils, each chosen for a specific nutritional or protective role. The name is an acronym: Soybean oil, Medium-chain triglycerides (MCTs), Olive oil, and Fish oil. Sold under the brand name SMOFlipid, the product is used in parenteral nutrition, the practice of delivering nutrients directly into the bloodstream when a patient cannot eat or absorb food through the gut. The blend represents what researchers call a “third-generation” lipid emulsion, designed to fix problems that earlier, simpler fat formulations caused, particularly excessive inflammation and liver damage.

Why Patients Need Fat Through an IV

When someone cannot eat for an extended period, whether because of major surgery, a bowel obstruction, short bowel syndrome, or extreme prematurity in newborns, clinicians deliver all their nutrition intravenously. Fat is a critical part of that package. It provides a dense source of calories, it carries fat-soluble vitamins (A, D, E, and K), and it supplies essential fatty acids that the human body cannot manufacture on its own. Humans lack the enzymes to make linoleic acid and alpha-linolenic acid, so those must come from an external source. For patients who depend entirely on IV nutrition, lipid emulsions are the only way to prevent essential fatty acid deficiency.¹

The first IV fat emulsions, introduced decades ago, were based entirely on soybean oil. These worked well for providing calories and essential fatty acids, but they came loaded with omega-6 polyunsaturated fatty acids. Over time, that heavy omega-6 load raised concerns. High omega-6 intake can fuel inflammatory pathways and suppress parts of the immune system, which is the last thing a critically ill patient needs. The second generation of emulsions tried to dial back the omega-6 by blending in MCTs or substituting olive oil for some of the soybean oil. SMOF lipids are a third-generation product that takes the strategy further by incorporating fish oil, which brings anti-inflammatory omega-3 fatty acids into the mix.²

What Each Oil Brings to the Blend

The four oils in SMOFlipid are not just thrown together for variety. Each one addresses a different nutritional or metabolic need, and the proportions are chosen to balance their effects. In a standard 20% SMOFlipid emulsion, the oil phase is roughly 30% soybean oil, 30% MCTs, 25% olive oil, and 15% fish oil.

Soybean oil is the legacy ingredient. It is rich in linoleic acid, the omega-6 essential fatty acid the body cannot make. A certain amount of soybean oil is necessary to prevent deficiency, but too much tilts the body’s fatty acid balance toward pro-inflammatory compounds. In SMOF, its share is reduced to roughly a third of what it would be in a pure soybean emulsion, delivering enough essential fatty acids without the inflammatory baggage.

Medium-chain triglycerides, derived from coconut or palm kernel oil, serve a different purpose. MCTs are shorter fat molecules that the body handles differently from the long-chain fats in soybean or olive oil. They are cleared from the blood faster and oxidized for energy more readily, making them an efficient fuel source that does not accumulate in tissues the way long-chain fats can.³ Early research showed that MCT-containing emulsions produced more ketone bodies during infusion without causing acidosis, and triglyceride levels rose far less than with conventional long-chain emulsions.⁴ In practical terms, MCTs give the patient usable energy quickly while being gentler on the liver.

Olive oil, rich in the monounsaturated fat oleic acid, is the immunologically quietest component. Unlike the polyunsaturated fats in soybean and fish oil, oleic acid is relatively inert when it comes to immune-cell signaling. Research on olive oil-based emulsions suggests they preserve immune function, reduce lipid oxidation in the blood, and are associated with fewer infections compared to high-omega-6 formulas.⁵ In SMOF, the olive oil fraction essentially acts as a neutral caloric backbone that dilutes the inflammatory potential of the soybean oil without introducing new immunological problems.

Fish oil is the ingredient that sets SMOF apart from earlier formulations. At 15% of the blend, it delivers the long-chain omega-3 fatty acids EPA and DHA. These are the same fats found in salmon and sardines, and they have well-documented anti-inflammatory effects. EPA and DHA reduce the production of inflammatory signaling molecules by replacing arachidonic acid (an omega-6 derivative) as the raw material cells use to make those signals. They also influence gene expression, dialing down the activation of transcription factors that drive inflammation.⁶ The fish oil fraction also brings alpha-tocopherol (vitamin E), which acts as an antioxidant, protecting cells and the emulsion itself from oxidative damage.

How the Anti-Inflammatory Effect Works

The inflammatory benefit of SMOF lipids comes primarily from the fish oil component, and the mechanism is more layered than simply “omega-3s are good for you.” When cells receive a steady supply of EPA and DHA, those fatty acids get incorporated into cell membranes, particularly in immune cells like monocytes and macrophages. Once embedded in the membrane, EPA and DHA physically displace arachidonic acid, the omega-6 fat that serves as the starting material for a family of strongly pro-inflammatory molecules. With less arachidonic acid available, the cell produces fewer of those inflammatory mediators.

Lab studies using fish oil emulsions have shown dose-dependent suppression of multiple inflammatory signals, including IL-6, TNF-alpha, IL-1-beta, and IL-8, in human monocytes stimulated with bacterial endotoxin.⁷ In clinical settings, a trial comparing SMOF to an olive/soybean oil emulsion in patients needing parenteral nutrition found that by day five, patients receiving SMOF had lower blood levels of IL-6, TNF-alpha, and soluble E-selectin, a marker of blood vessel inflammation.⁸

The evidence on inflammation is not perfectly uniform, though. A longer four-week study in adults found that IL-6 and soluble TNF receptor levels did not change over the study period in either the SMOF or control group.⁹ Another randomized trial found that TNF-alpha levels trended downward in the SMOF group while rising in the control group, but the difference did not reach statistical significance.¹⁰ A trial in patients undergoing gastrointestinal surgery found no difference in inflammatory markers or oxygen radical levels between SMOF and an MCT/LCT emulsion.¹¹ The picture that emerges is that SMOF tends to dampen inflammation, but the size and consistency of the effect varies with the patient population, the comparison product, and how long the emulsion is used.

Protecting the Liver

Liver damage is one of the most feared complications of long-term parenteral nutrition, especially in premature infants and patients with intestinal failure who may depend on IV feeding for months or years. The condition, sometimes called intestinal failure-associated liver disease or parenteral nutrition-associated cholestasis, involves a buildup of bile components in the liver that can progress to scarring and, in severe cases, liver failure. Older soybean oil-based emulsions are implicated in this process because their high content of plant sterols (phytosterols) and pro-inflammatory omega-6 fats can impair bile flow and promote liver inflammation.

SMOF lipids were designed in part to address this problem, and the clinical data in pediatric patients is encouraging. A comparison of pediatric patients receiving either a soybean oil emulsion or SMOF found that the rate of intestinal failure-associated liver disease was roughly a third as common in the SMOF group.¹² In preterm neonates, one study found that infants receiving SMOFlipid had about half the incidence of parenteral nutrition-associated cholestasis compared to those on an older formula, with lower peak direct bilirubin levels and shorter hospital stays.¹³

In adults on home parenteral nutrition over five years, a study tracking liver enzymes found no significant differences between SMOF and other emulsions for most liver markers, but the SMOF group did show a significant reduction in bilirubin concentration over the study period, suggesting a gentle liver-protective effect even in long-term use.¹⁴ In a four-week double-blind trial, adults receiving SMOF had lower mean concentrations of ALT, AST, and total bilirubin compared to controls, all remaining within normal ranges but trending in a favorable direction. The same study found that serious adverse events were significantly less common in the SMOF group.⁹

Antioxidant Effects and Fatty Acid Profiles

Beyond liver enzymes and inflammatory markers, SMOF lipids also shift the body’s fatty acid composition and oxidative stress markers. In the four-week adult trial, patients on SMOF showed significant increases in blood levels of EPA, DHA, and the omega-3-to-omega-6 ratio, both in plasma and in red blood cell membranes, while these values stayed flat in the control group. Serum alpha-tocopherol, the active form of vitamin E, also rose significantly in the SMOF group.⁹ That matters because vitamin E scavenges free radicals that damage cell membranes, and patients receiving parenteral nutrition are particularly vulnerable to oxidative stress.

A pilot study in patients on home parenteral nutrition compared oxidative stress markers across three lipid emulsions and found that people receiving SMOF had the lowest blood levels of malondialdehyde, a byproduct of lipid oxidation and a widely used marker of oxidative damage. The SMOF group also had the highest activity of glutathione peroxidase, an important antioxidant enzyme.¹⁵ These findings align with the theoretical advantage of the emulsion: the combination of fish oil omega-3s and the vitamin E enrichment work together to reduce the oxidative burden that parenteral nutrition can impose.

Results in Hospitalized and ICU Patients

A large pre-post study at a hospital that switched its entire parenteral nutrition protocol from a soybean oil emulsion to a four-oil emulsion found measurable improvements across several outcomes. ICU patients treated after the switch had roughly a 10% shorter hospital stay, a 10% shorter ICU stay, lower total bilirubin levels, and half the rate of urinary tract infections compared to patients treated before the switch.¹⁶ A review of the evidence in critical care patients concluded that SMOF-type emulsions have been associated with immunomodulatory benefits, better liver function, reduced hospital stays, and fewer hospital-acquired infections.¹⁷

In infants who underwent gastrointestinal surgery, a randomized trial found that those receiving a four-oil emulsion had lower white blood cell counts and lower C-reactive protein levels (a broad marker of inflammation) by the third postoperative day compared to infants on a standard emulsion. Omega-6 levels were also lower in the four-oil group, consistent with the intended fatty acid rebalancing.¹⁸

Use in Premature Infants and an Important Tradeoff

Premature babies are one of the populations most dependent on parenteral nutrition, sometimes for weeks, and they are also the most vulnerable to its complications. SMOF lipids have become increasingly common in neonatal intensive care units, but the evidence in this population reveals a nuanced picture rather than a straightforward win.

One study of very preterm infants found that SMOFlipid was associated with a significant reduction in bronchopulmonary dysplasia (a chronic lung disease of prematurity) compared to a soybean oil emulsion. However, the same study found that infants on SMOFlipid had lower weight gain during their hospital stay, particularly among males, and a higher rate of late-onset sepsis.¹⁹ The growth concern is worth watching. Fish oil’s anti-inflammatory properties, while beneficial for the lungs and liver, may also dampen certain growth-promoting signals. Whether this translates into meaningful long-term growth differences is not yet settled, but it underscores that the balance of benefits and risks in extremely premature infants is not identical to the balance in adults.

Safety and Triglyceride Handling

A basic safety concern with any IV fat emulsion is whether the body can clear the fat from the blood quickly enough to avoid dangerously high triglyceride levels. Across multiple trials, SMOF lipids have performed well on this front. An early randomized safety trial in surgical patients found that serum triglycerides, phospholipids, and total cholesterol remained within expected ranges and were comparable between SMOF and the control emulsion.²⁰ In preterm infants, triglyceride levels rose modestly and similarly in both SMOF and control groups over an eight-day treatment period.²¹

One interesting finding involves a head-to-head comparison between SMOF and an MCT/soybean oil blend in surgical neonates. Hypertriglyceridemia (triglycerides above 250 mg/dL) was about four times as common in the MCT/soybean group compared to SMOF, and mean triglyceride levels ran about 35 mg/dL higher throughout the study period.²² The MCT component in SMOF likely contributes to this advantage, given that MCTs are cleared from the blood and burned for energy faster than long-chain fats.

Cost and Hospital Economics

SMOF lipids cost more per bag than older soybean oil emulsions, and this has been a barrier to adoption in some settings. But several pharmacoeconomic analyses have found that the higher acquisition cost is offset by downstream savings. A modeling study of ICU patients estimated that using an omega-3-enriched emulsion reduced overall hospital stay by nearly two days, cut ICU stay by more than a day, and prevented about a third of hospital-acquired infections, resulting in a net saving of over $1,000 per patient.²³ A broader review of pharmacoeconomic data across multiple countries concluded that the clinical improvements associated with omega-3-containing emulsions more than offset their additional purchase price in every national scenario examined.²⁴

Mixing SMOF Lipids in Practice

In hospitals, parenteral nutrition is often compounded into a single bag called an “all-in-one” or total nutrient admixture that contains amino acids, glucose, electrolytes, vitamins, trace elements, and the lipid emulsion together. Because lipid emulsions are oil-in-water dispersions stabilized by egg phospholipid, their physical stability in these complex mixtures matters. If fat droplets merge into larger globules (a process called coalescence), the admixture can become unsafe to infuse.

Stability testing of all-in-one bags containing SMOFlipid for neonatal use found that the emulsion remained stable at room temperature for the first 24 hours, with fat droplets averaging about 348 nanometers in diameter and none exceeding about 1.2 micrometers. By 48 hours at room temperature, however, some droplets had grown to unacceptable sizes. Refrigerated storage at 4°C kept the emulsion stable for at least 48 hours with excellent uniformity.²⁵ For clinicians and pharmacists, the practical takeaway is that SMOF-containing admixtures should be refrigerated if they will not be used within 24 hours, a standard precaution that is now reflected in most compounding guidelines.

Where the Evidence Still Has Gaps

Despite the generally favorable profile, there are areas where the evidence on SMOF lipids is thin or mixed. Most of the strongest data comes from short-term use in hospitalized patients. Fewer randomized trials have followed patients on SMOF for months or years, though the five-year observational data in home parenteral nutrition patients showed stable liver function and a favorable bilirubin trend.¹⁴ The growth question in very preterm infants also remains open. And while individual trials point to reduced infections and shorter hospital stays, the magnitude of benefit varies considerably between studies, partly because different trials use different comparator emulsions. Beating a pure soybean oil product is a lower bar than beating an olive oil or MCT/soybean blend, and not all studies draw the same comparison.

There is also the matter of what SMOF cannot do. It is not a treatment for established liver disease; it is a strategy to reduce the risk of developing liver problems in the first place. Patients who already have advanced parenteral nutrition-associated liver disease may benefit from pure fish oil emulsions (which deliver a much higher omega-3 dose) rather than the moderate fish oil content in SMOF. The two products serve different purposes, and conflating them is a common source of confusion in clinical discussions.